CBDMD (YCBD) Ownership - Who owns CBDMD?

Key Takeaways

• YCBD is the ticker for cbdMD, Inc., a U.S.-based consumer wellness and hemp-derived CBD company listed on the NYSE American exchange.
• The company markets several brands, including cbdMD, Paw CBD, Bluebird Botanicals, ATRx Labs, and the Herbal Oasis THC beverage line.
• cbdMD recently acquired the operating assets of Twinlab, adding legacy supplement brands such as Twinlab, Reserveage, and Metabolife to diversify beyond hemp.
• Revenue is generated primarily through direct-to-consumer e-commerce, online marketplaces, and wholesale distribution to brick-and-mortar retailers.
• The company operates in a heavily regulated industry, making federal and state hemp and CBD rules a central risk factor for its business.

Introduction

cbdMD, Inc. is a consumer products company that develops, markets, and distributes hemp-derived CBD (cannabidiol) and other wellness products. Traded under the ticker YCBD, the company is headquartered in Charlotte, North Carolina, and is best known for its namesake cbdMD brand of tinctures, gummies, capsules, and topicals. Investors follow the company for its position in the CBD and broader wellness market, its portfolio of recognizable brands, and its ongoing efforts to diversify beyond hemp-derived products.

Main Profile

cbdMD, Inc. was formed in North Carolina in March 2015 under the name Level Beauty Group, Inc., later operating as Level Brands, Inc. before adopting the cbdMD name in May 2019. The company is led by CEO and CFO T. Ronan Kennedy and reports a workforce of roughly 42 employees. Its principal executive offices are located in Charlotte, North Carolina.

The company's business model centers on developing and selling branded wellness products across multiple channels. Its flagship cbdMD brand offers broad spectrum and full spectrum CBD products, including tinctures, gummies, topicals, capsules, and sleep, focus, and calming aids. The Paw CBD brand provides veterinarian-formulated products for pets, while ATRx Labs offers functional mushroom supplements focused on immunity, focus, digestive health, and mood. The Herbal Oasis line consists of hemp-derived, THC-infused social seltzers, and Bluebird Botanicals is a line of premium full spectrum CBD products.

In late 2026, cbdMD completed the acquisition of the operating assets of Twinlab, adding the Twinlab, Reserveage, Metabolife, and ResVitale supplement brands to its portfolio. The transaction marked a strategic move to diversify the company beyond hemp and to strengthen its presence in vitamins, nutritional supplements, and legacy retail channels.

cbdMD generates revenue through several primary revenue sources, including its own e-commerce websites, third-party e-commerce platforms, select distributors and marketing partners, and a variety of brick-and-mortar retailers. This multi-channel approach allows the company to reach both direct-to-consumer customers and wholesale retail accounts. The company operates in the healthcare and consumer wellness sector, competing against other CBD producers, supplement brands, and functional beverage companies for consumer attention and shelf space.

Why Investors Follow YCBD

Investors pay attention to cbdMD for its position in the CBD and broader wellness industry, a market shaped by evolving consumer demand for natural and functional health products. The company's portfolio spans multiple product categories—CBD, pet wellness, functional mushrooms, THC beverages, and traditional supplements—which gives it exposure to several consumer trends rather than a single niche.

The Twinlab acquisition is a notable long-term growth driver, as it adds decades-old brands with established retail relationships and reduces the company's reliance on hemp-derived revenue at a time of regulatory uncertainty. This diversification, combined with the company's focus on direct-to-consumer sales and margin discipline, forms a central part of its strategic positioning.

cbdMD's financial profile is characteristic of a small-cap growth company: it has historically reported net losses as it invests in brand-building and product expansion, while working toward profitability through cost reductions and portfolio optimization. Investors monitoring YCBD often track the company's ability to grow revenue, manage gross margins, and move toward break-even operating results.

Risks and Important Considerations

Investing in cbdMD carries several important risks. The company operates in a highly regulated industry, and changes to federal or state rules governing hemp, CBD, and THC products can have a material effect on its business. Recent federal legislation has proposed limits on THC content in hemp-derived consumable products, and the timing and final form of such rules remain uncertain—factors the company has identified as potentially material to its results.

The company also faces intense competition from both established consumer brands and numerous smaller CBD and supplement producers. Its small size and history of net losses mean it depends on access to capital and continued revenue growth. Customer concentration, reliance on wholesale retail partners, and broader shifts in consumer spending represent additional considerations. Finally, the CBD and wellness categories remain subject to changing consumer sentiment and scientific debate, which can influence demand over time.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies. Explore the AI Screener to refine your research and discover new market opportunities.

Conclusion

cbdMD, Inc. is a small-cap consumer wellness company that has built a multi-brand portfolio spanning CBD, pet products, functional mushrooms, THC beverages, and, following the Twinlab acquisition, traditional nutritional supplements. Its market position is defined by recognized brand names, a multi-channel distribution model, and an ongoing effort to diversify beyond hemp at a time of regulatory change. For investors interested in the consumer wellness and CBD sectors, YCBD represents a company whose long-term outlook is closely tied to regulation, brand execution, and its progress toward sustainable profitability.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations